Isogenica renews collaboration with the Royal Academy of Engineering to support students from under-represented groups
We are delighted to be working with the Royal Academy of Engineering as part of their Graduate Engineering Engagement Programme (GEEP).
The GEEP initiative supports students and recent graduates from under-represented groups, aiming to help these students take their first steps into industry roles and launch their careers.
According to research by the Royal Academy of Engineering, graduates from ethnic minority backgrounds are 13% to 17% less likely to transition into engineering roles than their white counterparts, with a similar lack of representation for graduates from lower socio-economic backgrounds.
This isn’t good enough. That’s why we are taking part in this excellent program, not only helping these students enter relevant industry roles, but also ensuring the industry is more equitable and inclusive as a whole.
Many of our talented Isogenica staff members have already signed up as mentors, panellists, or workshop facilitators, providing practical support. We will also be using this as an opportunity to learn how we can do better as a company. The training and support provided by GEEP will enable us to actively engage with students, learn from their unique lived experiences, and help us make Isogenica more inclusive – from our policies down to our day-to-day operations.
You can learn more about the GEEP programme here: https://raeng.org.uk/programmes-and-prizes/programmes/uk-grants-and-prizes/support-for-education/graduate-engineering-engagement-programme
Further Information
Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.
Contact